Molecular Formula | C29H23N7O2S2 |
Molar Mass | 565.67 |
Density | 1.483±0.06 g/cm3(Predicted) |
Solubility | DMSO : ≥ 125 mg/mL (220.98 mM) |
Appearance | powder |
Color | white to beige |
pKa | 9.11±0.10(Predicted) |
Storage Condition | 2-8°C |
Use | SC75741 is a widespread and potent NF-κB inhibitor with an IC50 of 200 nM for p65. SC75741 can block influenza viruses replication. SC75741 inhibits caspase activation and blocks nuclear output of caspase-mediated viral ribonucleoprotein (viralribonucleoproteins) by impairing DNA binding of NF-κB subunit p65, resulting in decreased expression of cytokines, chemokines and pro-apoptotic factors. |
Target | NF-κB |
In vitro study | SC75741 showed immunosuppressive activity by inhibiting proliferation of human PBMC with an IC50 of 2.2 μm. SC75741 Inhibits Influenza A and B by inhibiting the NF-κB-mediated signaling pathway at the transcriptional level Virus. In addition, SC75741 showed a high barrier effect on the development of antiviral variants. SC75741 showed immunosuppressive activity by inhibiting proliferation of human PBMC with an IC50 of 2.2 μm. SC75741 Inhibits Influenza A and B by inhibiting the NF-κB-mediated signaling pathway at the transcriptional level Virus. In addition, SC75741 showed a high barrier effect on the development of antiviral variants. |
In vivo study | After injection of H5N1 Virus, SC75741 (15 mg/kg, I. P.) reduced Virus replication and cytokine expression in the lungs of mice. after injection of H5N1 Virus, SC75741 (15 mg/kg, I. P.) reduced Virus replication and cytokine expression in the lungs of mice. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.768 ml | 8.839 ml | 17.678 ml |
5 mM | 0.354 ml | 1.768 ml | 3.536 ml |
10 mM | 0.177 ml | 0.884 ml | 1.768 ml |
5 mM | 0.035 ml | 0.177 ml | 0.354 ml |
biological activity | SC75741 is a potent NF-κB inhibitor with an EC50 of 200 nM. SC75741 is a potent NF-κB inhibitor with an EC50 of 200 nM. SC75741 is effective in blocking the spread of influenza Virus. |
in vitro study | SC75741 showed immunosuppressive activity by inhibiting human PBMC proliferation with an IC50 of 2.2 μm. SC75741 Inhibits Influenza A and B by inhibiting the NF-κB-mediated signaling pathway at the transcriptional level Virus. In addition, SC75741 showed a high barrier effect on the development of antiviral variants. SC75741 showed immunosuppressive activity by inhibiting proliferation of human PBMC with an IC50 of 2.2 μm. SC75741 Inhibits Influenza A and B by inhibiting the NF-κB-mediated signaling pathway at the transcriptional level Virus. In addition, SC75741 showed a high barrier effect on the development of antiviral variants. |
in vivo study | after injection of H5N1 Virus, SC75741 (15 mg/kg, I. P.) reduces Virus replication and cytokine expression in the mouse lung. after injection of H5N1 Virus, SC75741 (15 mg/kg, I. P.) reduced Virus replication and cytokine expression in the lungs of mice. |
characteristic | NF-Δb selective inhibitor. |
Target | TargetValue NF-Δb (Cell-based NF-Δb reporter gene assay) 200 nM(EC50) |
Target | Value |
NF-κB (Cell-based NF-κB reporter gene assay) | 200 nM(EC50) |